{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002721","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.415676+00:00","generated_at":"2026-06-20T17:22:10.314970+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel prelim FY2022 rev ~$164-165M; MACI arthro launch accelerated to 2024; NexoBrid approved","bullets":["Full-year 2022 total revenue expected ~$164-165M; MACI rev ~$132M at high end of guidance.","Q4 MACI revenue growth ~24% YoY; 10th straight quarter of positive adjusted EBITDA and operating cash flow.","Cash and investments ~$140M, no debt as of Dec 31, 2022.","NexoBrid FDA approved Dec 28, 2022 for eschar removal in thermal burns; U.S. commercial launch expected Q2 2023.","MACI arthroscopic delivery human factors study planned for 2023; commercial launch now expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002721","json":"https://secwatch.observer/filing/0001104659-23-002721.json","markdown":"https://secwatch.observer/filing/0001104659-23-002721.md","text":"https://secwatch.observer/filing/0001104659-23-002721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/tm232747d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:22:10.314970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02c95aacff7fa5c5b9557394ecc9a2194a7bd321","claim":"Vericel Corp reported the year ended December 31, 2022 results: revenue approximately $164 to $165 million.","evidence_excerpt":"Total net revenue for full-year 2022 expected to be approximately $164 to $165 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"approximately $164 to $165 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"d102b44eb14f4b644a9f7daa05b1542593a6342d","claim":"Vericel Corp reported preliminary financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887359/000110465923002721/0001104659-23-002721-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}